New data for Roche ’s OCREVUS show that after 10 years of treatment 77% of people with relapsing multiple sclerosis were free from disability progression and 92% continue to walk unaided
10-year efficacy data highlight OCREVUS ’ impact on preventing disability progression and maintaining mobility in both relapsing and progressive forms of multiple sclerosis (MS)10-year safety data from over 6,000 patients continue to reinforce consistent long-term safety profile of OCREVUSMore than 3,200 women with MS treated with OCREVUS reported no increased risk in adverse pregnancy and infant outcomes with real-world analyses showing low risk of relapse during and after pregnancyOCREVUS controlled disease activity and progression over one year in Black and Hispanic / Latinx people with MSBasel, 12 October 2023 - Roch...
Source: Roche Investor Update - October 12, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions
Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on OCREVUS levels in the blood over 12 weeksOCREVUS subcutaneous injection was comparable to IV infusion in providing rapid and sustained depletion of B cells and near-complete suppression of MRI lesion activity in the brain over 24 weeksThe safety profile of OCREVUS subcutaneous injection was consistent with the well-established safety profile of OCREVUS IV infusionThe 10-minute subcutaneous injection has potential to improve the treatment experience and expand usage for people with multiple sclerosis (MS) in centres...
Source: Roche Media News - October 11, 2023 Category: Pharmaceuticals Source Type: news
Roche ’s OCREVUS twice-yearly, 10-minute subcutaneous injection was non-inferior to intravenous infusion and provided near-complete suppression of brain lesions
Late-breaking Phase III results show subcutaneous injection was non-inferior to intravenous infusion based on OCREVUS levels in the blood over 12 weeksOCREVUS subcutaneous injection was comparable to IV infusion in providing rapid and sustained depletion of B cells and near-complete suppression of MRI lesion activity in the brain over 24 weeksThe safety profile of OCREVUS subcutaneous injection was consistent with the well-established safety profile of OCREVUS IV infusionThe 10-minute subcutaneous injection has potential to improve the treatment experience and expand usage for people with multiple sclerosis (MS) in centres...
Source: Roche Investor Update - October 11, 2023 Category: Pharmaceuticals Source Type: news
Opinion: American Youth Are Increasingly Indifferent to Jewish Suffering and Sympathetic to an Ancient Evil
AP Photo/Stephan Savoia America’s youth are increasingly ignorant of and indifferent toward the suffering of the Jewish people. In the days since terrorists launched a barbaric attack in southern Israel that included the mass kidnapping, rape, and murder of Israeli civilians, university student…#jewish #israel #israeli #harvarduniversity #gaza #palestinian #palestine #zionist #hamas #universityofvirginia (Source: Reuters: Health)
Source: Reuters: Health - October 10, 2023 Category: Consumer Health News Source Type: news
Tamoxifen Fails to Deliver on Clinical Promise for Duchenne Muscular Dystrophy
(MedPage Today) -- Repurposed tamoxifen failed to delay disease progression as an adjunct to corticosteroids among boys with Duchenne muscular dystrophy (DMD), the phase III TAMDMD trial showed.
In an intention-to-treat population, no significant... (Source: MedPage Today Neurology)
Source: MedPage Today Neurology - October 10, 2023 Category: Neurology Source Type: news
Majority of newborn babies with spinal muscular atrophy (SMA) treated with Roche ’s Evrysdi able to sit independently after 1 year of treatment
RAINBOWFISH study met its primary endpoint with 80% of babies sitting without support for at least five seconds after 1 year of Evrysdi treatment – without treatment these babies would never be able to sitAll babies were able to swallow and feed orally and none required permanent ventilationEvrysdi is the only non-invasive SMA therapy and is approved in over 100 countries with more than 11,000 patients treated globallyBasel, 04 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented positive results from the primary analysis of the ongoing RAINBOWFISH study assessing the efficacy and safety of Evrysdi ® (risdi...
Source: Roche Media News - October 4, 2023 Category: Pharmaceuticals Source Type: news
Majority of newborn babies with spinal muscular atrophy (SMA) treated with Roche ’s Evrysdi able to sit independently after 1 year of treatment
RAINBOWFISH study met its primary endpoint with 80% of babies sitting without support for at least five seconds after 1 year of Evrysdi treatment – without treatment these babies would never be able to sitAll babies were able to swallow and feed orally and none required permanent ventilationEvrysdi is the only non-invasive SMA therapy and is approved in over 100 countries with more than 11,000 patients treated globallyBasel, 04 October 2023 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today presented positive results from the primary analysis of the ongoing RAINBOWFISH study assessing the efficacy and safety of Evrysdi ® (risdi...
Source: Roche Investor Update - October 4, 2023 Category: Pharmaceuticals Source Type: news
Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD
Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitorfenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS efficacy and safety data show significant benefit in slowing long-term disability progression and consistent long-term safety profile in MSAdditional OCREVUS real-world and clinical data show impact for underrepresented populations including more than 3,200 pregnant women and Black and Hispanic/Latinx patients with MSLonger-term safety data and late-breaking efficacy data from Phase III trial of ENSPRYNG (satralizumab) inneurom...
Source: Roche Media News - October 2, 2023 Category: Pharmaceuticals Source Type: news
Roche to present new key clinical and real-world data at ECTRIMS-ACTRIMS 2023 showcasing strength of long-term outcomes in MS and NMOSD
Late-breaking results from Phase III trial of OCREVUS (ocrelizumab) subcutaneous injection and Phase II trial of BTK inhibitorfenebrutinib in multiple sclerosis (MS) will be presented10-year OCREVUS efficacy and safety data show significant benefit in slowing long-term disability progression and consistent long-term safety profile in MSAdditional OCREVUS real-world and clinical data show impact for underrepresented populations including more than 3,200 pregnant women and Black and Hispanic/Latinx patients with MSLonger-term safety data and late-breaking efficacy data from Phase III trial of ENSPRYNG (satralizumab) inneurom...
Source: Roche Investor Update - October 2, 2023 Category: Pharmaceuticals Source Type: news
A populist leader, sympathetic to Putin's Russia, could be about to win elections in Slovakia
Slovakia heads to the polls on Saturday for a general election that threatens to further fracture European Union support for Ukraine. The main reason? A front-running contender to be its next prime minister has fiercely criticized Ukraine and the EU's anti-Russian position on the war, and vowed…#slovakia #ukraine #antirussian #robertfico #ako #joj #progressiveslovakia #smer #jánkuciak #martinakušnírová (Source: Reuters: Health)
Source: Reuters: Health - September 29, 2023 Category: Consumer Health News Source Type: news
Neuro-cardiovascular responses to sympathetic stimulation in fighter pilots - Dos Santos Rangel MV, de S á GB, Farinatti P, Borges JP.
INTRODUCTION: The chronic effects of regular exposure to high acceleration levels (G-force) on the neuro-cardiovascular system are unclear. We compared the mean arterial pressure (MAP) and cardiac autonomic modulation between nonpilots (NP) vs. military fi... (Source: SafetyLit)
Source: SafetyLit - September 25, 2023 Category: International Medicine & Public Health Tags: Ergonomics, Human Factors, Anthropometrics, Physiology Source Type: news
The FSHD Society's September 23 podcast gives voice to thousands fighting FSH muscular dystrophy
The livestream will feature patients, families and allies who are "walking and rolling" across the U.S. and Canada to raise awareness and funds for the debilitating condition RANDOLPH, Mass., Sept. 22, 2023 /PRNewswire-PRWeb/ -- The FSHD Society announced that this Saturday, September 23,... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 22, 2023 Category: Pharmaceuticals Tags: FVT Source Type: news
Brickbat: Up in Smoke
As part of what they say is an effort to curb smoking, French officials have proposed banning disposable vapes. "They create a reflex, a gesture, which children get used to, and then end up being drawn to tobacco," said Prime Minister Élisabeth Borne. Officials also said the ban would be good for…#élisabethborne #smoke #reasoncom (Source: Reuters: Health)
Source: Reuters: Health - September 20, 2023 Category: Consumer Health News Source Type: news
Biden Can ’t Resist the ‘River of Power’
It’s been a week of “step away” stories for President Biden, the most significant of which came from the normally sympathetic David Ignatius of the Washington Post. His argument was clear and gently put: Mr. Biden is an admirable figure who’s won great victories, but age has taken too much from…#davidignatius (Source: Reuters: Health)
Source: Reuters: Health - September 14, 2023 Category: Consumer Health News Source Type: news
Filmmakers to champion the FSHD Society's Los Angeles Walk & amp; Roll to Cure FSH muscular dystrophy
For the team behind the forthcoming movie, Good Bad Things, it's personal LOS ANGELES, Sept. 14, 2023 /PRNewswire-PRWeb/ -- The team behind the forthcoming movie, "Good Bad Things," will be coming out this September 17th to support to the FSHD Society's sixth annual Walk & Roll to Cure... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 14, 2023 Category: Pharmaceuticals Source Type: news
